JAVELIN: avelumab another spear to fight urothelial carcinoma

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5.

Authors

Aly-Khan A Lalani¹, Bradley A McGregor¹, Guru P Sonpavde¹, Toni K Choueiri²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: Toni_Choueiri@dfci.harvard.edu.

PMID: 29217289
DOI: 10.1016/S1470-2045(17)30901-4

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell
Humans
Urologic Neoplasms*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
avelumab